Skip to main content
. 2016 Apr 26;114(9):986–994. doi: 10.1038/bjc.2016.72

Table 5B. Progression-free survival in patients with hepatocellular carcinoma enrolled in part 2 and treated at the RP2D.

Patient number Progression-free survival, days
03–036 336
03–039 34
03–041 52
03–043 133
03–044 277a

Abbreviation: RP2D=recommended phase II dose.

a

Censored observation.